Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12932568 | 0.87 | CHRNB2 (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL23323081 | 0.84 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3538857 | 0.83 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL23487074 | 0.81 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL23323101 | 0.81 | CHRNA7 (0.35) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL24775061 | 0.81 | CHRNA7 (0.35) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL29534943 | 0.79 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1795660 | 0.78 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1795413 | 0.78 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1797595 | 0.78 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | CHRNB2 4503/4885CHRNA4 4874/4885CHRNB4 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.